Back

Effectiveness of BNT162b2 COVID-19 Vaccination in Children Aged 5-17 Years in the United States

2023-09-08 public and global health Title + abstract only
View on medRxiv
Show abstract

ImportanceCOVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. ObjectiveTo estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children. DesignA cohort study of children aged 5-17 years vaccinated with BNT162b2 matched with unvaccinated children. SettingParticipants identified in Optum and CVS Health insurance administrative ...

Predicted journal destinations